Background-We tested the hypothesis that correction of hyperlipidemia improves coronary vasodilator response and maximal perfusion in myocardial regions having substantial impairment of pretreatment vasodilator capacity. Methods and Results-Measurements of myocardial blood flow were made with PET [
Background-We tested the hypothesis that correction of hyperlipidemia improves coronary vasodilator response and maximal perfusion in myocardial regions having substantial impairment of pretreatment vasodilator capacity. Methods and Results-Measurements of myocardial blood flow were made with PET [ 13 N]ammonia in 12 patients with ischemic heart disease (11 men; age, 65Ϯ8 years [meanϮSD] ) at rest and during adenosine at 70 and then 140 g ⅐ kg Ϫ1 ⅐ min Ϫ1 for 5 minutes each before and Ϸ4 months after simvastatin treatment (40 mg daily). Simvastatin reduced LDL (171Ϯ13 before versus 99Ϯ18 mg/dL after simvastatin, PϽ0.001) and increased HDL (39Ϯ8 versus 45Ϯ9 mg/dL, PϽ0.05). Myocardial segments were classified on the basis of pretreatment blood flow response to 140 g ⅐ kg Ϫ1 ⅐ min Ϫ1 adenosine as normal (flow Ն2 mL ⅐ min Ϫ1 ⅐ g
Ϫ1
) or abnormal (flow Ͻ2 mL ⅐ min Ϫ1 ⅐ g
).
In normal segments, baseline myocardial blood flow (0.95Ϯ0.32) increased (PϽ0.001) at both low-(1.62Ϯ0.81) and high-(2.63Ϯ0.41) dose adenosine and was unchanged both at rest and with adenosine after simvastatin. In abnormal segments, myocardial blood flow at rest (0.73Ϯ0.19) increased at low-(1.06Ϯ0.59, PϽ0.02) and high-(1.29Ϯ0.33, PϽ0.01) dose adenosine. After simvastatin, myocardial blood flow increased more compared with pretreatment at both low-(1.37Ϯ0.66, PϽ0.05 versus pretreatment) and high-(1.89Ϯ0.79, PϽ0.01 versus pretreatment) dose adenosine. Conclusions-Short-term lipid-lowering therapy increases stenotic segment maximal myocardial blood flow by Ϸ45%. The mechanism involves enhanced, flow-mediated dilation of stenotic epicardial conduit vessels and may account at least in part for the efficacy of lipid lowering in secondary prevention trials and in reducing ischemic episodes in ambulatory patients.
(Circulation. 1998;98:1291-1296.)
Key Words: blood flow Ⅲ ischemia Ⅲ heart diseases Ⅲ simvastatin R ecent studies of patients at risk for ischemic heart disease have shown that hyperlipidemia impairs maximal vasodilator response to dipyridamole in myocardial segments with presumed normal epicardial vessels [1] [2] [3] [4] and is thought to reflect a microvascular abnormality present at an early stage of atherosclerosis. The effects of hyperlipidemia and its correction on coronary vasodilator function in patients with overt ischemic heart disease and substantial impairment of baseline coronary dilator capacity are less well studied. Reduced perfusion defect size 5, 6 and improved reactivity of epicardial conduit vessels [7] [8] [9] have been found after successful lipid-lowering therapy, although data on absolute myocardial blood flow have not been reported. Enhanced flow-mediated dilation of stenotic epicardial coronary vessels, presumably related to improved endothelial function after treatment of hyperlipidemia, could result in augmented myocardial blood flow. 5, 10 However, the magnitude of the effect is not known, and enhancement of coronary microvascular dilator capacity also could play a role.
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It is possible to separate the contributions of conduit artery and microvascular dilation by comparing flow responses of segments with distinctly abnormal baseline dilator capacity, indicative of hemodynamically significant coronary artery stenosis, to those of functionally normal segments of the same patients in which conduit vessel dilation contributes little to the myocardial blood flow response to adenosine. Accordingly, this study tests the hypothesis in humans with ischemic heart disease that correction of hyperlipidemia improves coronary vasodilator function and myocardial perfusion in segments with substantial impairment of baseline dilator reserve by a mechanism involving primarily flow-mediated dilation of conduit vessels.
Methods

Patient Population
Patients with overt ischemic heart disease were recruited for this study after approval was obtained from both the Radiation Safety and the Human Studies committees of the Massachusetts General Hospital. Twelve subjects (11 men; age, 65Ϯ8 years) were enrolled after written informed consent was obtained. Subjects were selected on the basis of a history of positive exercise stress test, triglycerides level Ͻ400 mg/dL, and an LDL level Ͼ160 mg/dL who were not on lipid-lowering therapy. Subjects were excluded if there was history of active tobacco abuse or diabetes mellitus.
Study Protocol
Subjects were treated with simvastatin 40 mg daily for 4.8Ϯ1.0 months. Cholesterol, triglycerides, and HDL levels were measured in the Clinical Chemistry Laboratory of the Massachusetts General Hospital before, during, and after lipid-lowering therapy. LDL levels were calculated according to the method of Friedwald et al.
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Exercise tolerance was measured with a standard Bruce treadmill protocol before the start of the study. Antianginal medications were continued before the stress test.
Positron Emission Tomography
PET imaging was performed on a whole-body tomograph (Scanditronix PC4096, GE Medical Systems) in patients after an overnight fast. 12, 13 Cardiac medications were continued as prescribed. Briefly, images were acquired simultaneously in 15 contiguous sections, with a center-to-center separation of 6.5 mm. After the patients were positioned in the scanner, a 10-minute transmission scan was performed to correct the emission data for attenuation. Patients underwent PET imaging with [ 13 N]ammonia at rest and during a 5-minute intravenous infusion of adenosine at 70 and then 140 g ⅐ kg Ϫ1 ⅐ min Ϫ1 . Dynamic data acquisition was begun 2 minutes after initiation of intravenous adenosine infusion and just before intravenous injection of Ϸ25 mCi [ 13 N]ammonia over Ϸ30 seconds. Data were collected for the first 3 minutes at 6 frames per minute and then at 2 frames per minute for 6 minutes. Radioactivity was allowed to decay for Ϸ30 minutes before the next scan.
Attenuation-corrected [ 13 N]ammonia images were reconstructed with a conventional filtered back-projection algorithm as 128ϫ128 pixel images in the transverse plane. Parametric (K1) images for rest and stress conditions were generated from the dynamic images by use of a previously described computer program. 12 The K1 images were then used for analysis of myocardial blood flow by placing circular regions of interest (nϭ8) over standard areas of short-axis rings corresponding to the proximal, middle, and distal thirds of the left ventricle. 13 A patient-based analysis of myocardial blood flow at rest and in response to adenosine before and after simvastatin treatment was performed. This was accomplished by taking all normal segments, defined as having myocardial blood flow Ն2 mL ⅐ min Ϫ1 ⅐ g Ϫ1 with high-dose adenosine, 12, 14 and averaging them together to obtain a single value of blood flow for each patient at each stage of the protocol before and after simvastatin. Abnormal segments for each patient, defined as having myocardial blood flow Ͻ2 mL ⅐ min Ϫ1 ⅐ g Ϫ1 with high-dose adenosine, 12, 14 were combined in the same fashion.
Myocardial conductance (G) was computed as follows: Gϭ(MBF/ MAP)ϫ1000, where MBF is myocardial blood flow (mL ⅐ min Ϫ1 ⅐ g Ϫ1 ) and MAP is mean arterial pressure (mm Hg). MAP in turn was computed as follows: MAPϭDAPϩ(0.5ϫPP), where DAP is diastolic arterial pressure and PP is pulse pressure
Statistical Analysis
Data are expressed as meanϮSD. The significance of changes in group mean values was assessed with ANOVA and appropriate multiple contrasts test (Statview and SuperAnova, Abacus Concepts). Paired t tests were used to evaluate the significance of changes in hemodynamics, myocardial blood flow data, and serum lipid levels after simvastatin treatment. Linear regression analysis was used to assess the relationship between group mean values of myocardial conductance and adenosine dose before and after simvastatin. Values of PϽ0.05 were considered significant.
Results
Patient Characteristics
There were 11 men and 1 woman (age, 65Ϯ8 years [range, 52 to 74 years]). The 1 woman did not take hormonal replacement therapy. Two patients had histories of prior myocardial infarction. No patient had prior coronary revascularization. Medications (Table 1) were not changed during the trial. Cardiac catheterization data were available for 7 of 12 patients, of whom 5 had single-vessel coronary artery disease (70% lumen diameter reduction) and 2 had double-vessel disease.
Serum Lipids and Stress Test Results
Total cholesterol declined from 235Ϯ17 to 162Ϯ19 mg/dL (PϽ0.001), while triglycerides were unchanged (125Ϯ72 to 97Ϯ45 mg/dL). There was a 42Ϯ9% reduction in LDL (171Ϯ13 before versus 99Ϯ18 mg/dL after simvastatin, PϽ0.001) and a 17Ϯ23% increase in HDL (39Ϯ8 versus 45Ϯ9 mg/dL, PϽ0.05).
Patients exercised for 6.9Ϯ2.8 minutes. Peak heart rate was 132Ϯ26 bpm and was 85Ϯ19% of age-predicted maximum. The peak double product was 22 213Ϯ6758 mm Hg/min. End point for exercise stress was fatigue in all but 2 patients (1 stopped for chest pain and the other because of ventricular tachycardia, which reverted to sinus rhythm without treatment). It should be noted that 7 of 12 patients experienced typical angina during the test (including the 1 who stopped because of it), and 10 of 12 exhibited Ն1-mm horizontal ST-segment depression.
Regional Myocardial Blood Flow
Hemodynamics Hemodynamic parameters remained unchanged compared with control values at low-dose adenosine both before and after simvastatin (Table 2 ). However, in response to highdose adenosine, heart rate increased significantly and arterial Myocardial conductance increased significantly versus control values (PϽ0.001) in response to low-and high-dose adenosine both before and after lipid-lowering therapy. The magnitude of the responses to each dose of adenosine was comparable before and after treatment and was consistent from patient to patient (Figure 1 ). The ratio of posttreatment to pretreatment conductance was 0.99Ϯ0.28 at rest, 1.17Ϯ0.40 at low-dose adenosine (PϭNS), and 1.04Ϯ0.42 at high-dose adenosine (PϭNS) (see Tables 3 and 4 and Figure 1 ).
Myocardial Blood Flow and Conductance: Abnormal Segments
Myocardial blood flow at rest was 0.73Ϯ0.19 and increased at both low-(1.06Ϯ0.59, PϽ0.02) and high-(1.29Ϯ0.33, PϽ0.01) dose adenosine. After treatment with simvastatin, myocardial blood flow at rest was 0.74Ϯ0.18 (PϭNS versus before simvastatin) and again increased in response to both low-(1.37Ϯ0.66, PϽ0.01) and high-(1.89Ϯ0.79, PϽ0.001) dose adenosine. The magnitude of blood flow increase to adenosine after simvastatin treatment was greater compared with pretreatment both at low (Pϭ0.05) and high (PϽ0.02) doses of simvastatin.
Myocardial conductance increased significantly compared with control values (PϽ0.001) in response to both low-and high-dose adenosine both before and after simvastatin therapy. The magnitude of the responses to each dose of adenosine, however, was greater compared with pretreatment both at low-(PϽ0.05) and high-(PϽ0.01) dose adenosine ( Figure  2 ). The response was consistent from patient to patient as demonstrated by Figure 3 , which illustrates the ratio of posttreatment to pretreatment conductance for each. The ratio increased from 1.04Ϯ0.32 at rest to 1.32Ϯ0.41 at low-dose adenosine (PϽ0.05) and to 1.47Ϯ0.40 at high-dose adenosine (PϽ0.005) (see Tables 3 and 4 and Figures 2 and 3) .
Discussion
Principal Findings
This study tested the hypothesis that short-term lipidlowering therapy would enhance coronary vasodilator capacity in myocardial segments having substantial impairment of pretreatment vasodilator function. The data obtained clearly support this hypothesis (Figure 2) . A left shift in the adenosine dose-response curve in abnormal zones after lipidlowering therapy occurred and may be explained by improved vasodilator capacity in conduit arteries, microvessels, or both. Although at first glance enhanced microvascular dilation is an attractive mechanism, it appears unlikely because improvement was confined to abnormal zones. Neither maximal myocardial blood flow nor conductance of normal zones improved after simvastatin. Had microvascular dilator function been enhanced by lipid lowering, then one would have expected normal zones, which were not at maximal potential at baseline, also to show improvement. Improved vasodilator capacity caused by substantial regression of epicardial stenosis in conduit vessels after only 4 months of lipid-lowering therapy is most unlikely. [15] [16] [17] Thus, enhanced flow-mediated dilation 18, 19 after lipid-lowering therapy, particularly at the site of hemodynamically significant coronary stenosis, appears to be the most likely mechanism responsible. This is especially true given the steep nature of the stenosis pressure-flow relationships for lesions capable of causing a substantial reduction in maximal myocardial flow with adenosine. 20 -23 Although normal segments had flow response to maximal adenosine Ն2 mL ⅐ min Ϫ1 ⅐ g
Ϫ1
, the absolute value on average (2.63Ϯ0.41) was less (PϽ0.05) than that of normal volunteers studied in our laboratory (3.24Ϯ0.87). 13 This is consistent with prior reports that vasodilator function of myocardial segments with anatomically mild or even no coronary stenosis may be reduced in patients with ischemic heart disease. 13, 24 Failure of microvascular dilator function to improve with lipid-lowering therapy in these patients could reflect any of several factors, including (1) longer duration and more extensive disease in patients with manifest ischemic heart disease, (2) inadequate duration of simvastatin therapy, or (3) a combination of both factors. In any event, it is important to stress that normal segments in fact had room to improve and thus that the absence of change cannot be attributed to the possibility that they were at maximal dilator potential to begin with.
The fact that conduit artery dilator function improved and microvascular function did not may be related to a variety of factors. Flow-mediated vasorelaxation is induced by sheer stress on the vessel wall, which in turn causes release of nitric oxide and other vasodilating compounds by the endothelium. 18, 19, [25] [26] [27] Pulse pressure in particular is greater in conduit vessels and could contribute to apparent earlier improvement in endothelial function vis a vis the microcirculation. Furthermore, although lipid-lowering therapy improves endothelial function, [7] [8] [9] it is possible that other endothelium-derived dilators (eg, prostacyclin and endothelium-derived hyperpolarizine factor) recover at different rates or play more-or less-important roles, depending on the level of the coronary circulation studied. Such factors could account for the variation in degree of recovery of endothelial function at different levels of the coronary circulation.
Although adenosine is predominantly an endotheliumindependent vasodilator, 28,29 Smits et al 30 found a clear in vivo contribution of endothelium-derived nitric oxide to adenosine-mediated vasodilation. Accordingly, improved responsiveness of conduit vessels to adenosine after simvastatin may be related to recovery of endothelial nitric oxide release, which has been shown to play an important role in epicardial dilation related to changes in pulse pressure. [25] [26] [27] Flowmediated dilation also has been associated with other favorable alterations of stenosis geometry beyond limited increases in minimum lumen diameter. 10 These changes also could have played a role in enhancing maximal myocardial blood flow with adenosine 10, 31 and may further explain why improvement was confined to abnormal segments. Indeed, both the baseline level of flow reserve ratio of abnormal segments (1.8; Table  3 ) and the level of improvement (2.5) in the present study corresponded closely to quantitative coronary angiographic measurements of stenosis geometry and flow reserve of severe stenoses before (1.9) and after (2.8) aggressive risk factor modification, including 20% total cholesterol reduction, in the Lifestyle Heart Trial.
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Literature Review
Several prior studies in this area have focused on vasodilator function in normal myocardial segments of hypercholesterolemic patients without manifest ischemic heart disease. [1] [2] [3] [4] Reduced maximal vasodilator response to dipyridamole was documented in each and was thought to reflect impaired endothelial and/or vascular smooth muscle function presumably at the microvascular level. Studies of patients with manifest ischemic heart disease have assessed the effects of lipid-lowering therapy on reactivity of epicardial coronary vessels [7] [8] [9] and myocardial perfusion defect size 5, 6 but have not reported on myocardial blood flow per se. Lipid lowering plus antioxidant therapy in patients with ischemic heart disease has been shown to either blunt or reverse constriction of epicardial coronary vessels to acetylcholine. [7] [8] [9] In 2 other studies, myocardial perfusion defect size declined after lipidlowering therapy. 5, 6 The mechanism of reduction in defect size was hypothesized to involve a combination of improved flow-dependent, endothelium-mediated, epicardial dilation and enhanced microvascular dilation. 5 Proof of improved function at the microvascular level, however, was unavailable because absolute measurements of myocardial blood flow in normal and abnormal areas were not obtained. The present study demonstrates for the first time that maximal myocardial blood flow of segments with marked impairment of flow reserve is augmented by lipid-lowering therapy and that enhanced conduit artery dilation alone is sufficient to account for the effect.
Study Limitations
The absence of coronary arteriography in all patients should not be construed as a limitation in this investigation, which evaluated physiological responses of the coronary circulation to lipid-lowering therapy. Hyperemic blood flow has an inverse, geometric relationship to anatomic coronary stenosis severity. 20 -23 Myocardial segments supplied by coronary vessels with little or no stenosis (Ͻ50% area reduction) have blood flow with dipyridamole Ͼ2 mL ⅐ min Ϫ1 ⅐ g
Ϫ1
, whereas these with severe stenosis (Ͼ90% area reduction) have myocardial blood flow Ϸ1 mL ⅐ min Ϫ1 ⅐ g
. 21 Similar data were obtained in the present study with adenosine, a more potent coronary dilator than dipyridamole. 32, 33 We have also shown that maximal myocardial blood flow Ͼ1.65 mL ⅐ min Ϫ1 ⅐ g Ϫ1 with adenosine has very high negative predictive accuracy (91%) for exclusion of moderate to severe coronary artery stenosis (ie, minimum lumen diameter Ͻ1.26 mm in 3-mm diameter artery) and that 30 of 31 (97%) moderate to severe stenoses had maximal myocardial blood flow with adenosine Ͻ1.65 mL ⅐ min Ϫ1 ⅐ g
. 12 Thus, although the focus of the present study was physiological, previous angiographic and physiological investigations in humans with ischemic heart disease 12,20 -22 support the approach adopted in the present investigation.
The intensive nature of the present study and the need for radiation exposure before and after therapy made it impractical to have a placebo-control group or to use a crossover study design. Instead, each patient served as his or her own control. Moreover, an internal control was present in the form of the normal zones that were unchanged in terms of blood flow responses over the course of the study. Thus, the constancy of hemodynamic and normal zone blood flow measurements documents the reproducibility of experimental methods and argues strongly against a nonspecific or placebo effect accounting for improved abnormal segment flow. The stability of PET measurements of myocardial blood flow in our patients also was demonstrated by the fact that the posttreatment-to-pretreatment conductance ratio for both normal and abnormal segments did not differ from unity at rest. Spontaneous improvement confined to abnormal zones only is also most unlikely because a prior report 5 demonstrated deterioration of abnormal zone perfusion with return to pretreatment status on withdrawal of short-term (3 months) lipid-lowering therapy in patients with ischemic heart disease. Accordingly, in the short term, the natural tendency of abnormal zone vasodilator capacity is to remain abnormal.
Conclusions
In the present study of patients with manifest ischemic heart disease, coronary vasodilator function improved substantially in myocardial segments with distinctly abnormal dilator capacity before treatment. Segments with dilator capacity in the normal range, however, failed to improve. Taken together, these data indicate that short-term lipid-lowering therapy improved endothelium-dependent, flow-mediated dilation of stenotic conduit arteries but not microvessels. The magnitude of the effect was substantial, with an increase in maximal myocardial blood flow of Ϸ45% (Figure 2 ). Clinically, the data demonstrate a potential mechanism through which lipid-lowering therapy improves prognosis in secondary prevention trials 34 and reduces the frequency of ischemic episodes in ambulatory patients 35 in the face of only minimal improvement in anatomic coronary stenosis severity. [15] [16] [17] 
